TZ Group

Tiziana Life Sciences is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune and inflammatory diseases as well as oncology. The company's lead candidate, foralumab, is the only fully human anti-CD3 monoclonal antibody in clinical development, uniquely designed for nasal or oral administration to induce systemic immune tolerance. Tiziana is currently advancing foralumab in Phase 2 trials for non-active secondary progressive multiple sclerosis (naSPMS) and exploring its potential in other neurodegenerative conditions like Alzheimer's disease. Additionally, the company is developing milciclib, a small molecule pan-CDK inhibitor, for the treatment of hepatocellular carcinoma and other solid tumors.